

Ramalingam, Suresh

Board Member Information

Institution/Organization

Winship Cancer Institute of Emory University

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

SSR

Disclosure of Potential Conflicts

SSR

COI Disclosure

Disclosures

Amgen: Consultant, Institutional, Personal, The vast majority of the funds are directed to the institution to support research.

Bristol Myers Squibb: Consultant Institutional, Personal, the vast majority of the funds are directed to the institution to support research.

Astra Zeneca: Consultant Institutional, Personal

Advaxis: Research support, Institutional

Genmab: Consultant and research support Institutional, Personal

Merck: Consultant and research support Institutional, Personal

Glaxo Smithkline: Consultant and research support Institutional, Personal

Eisai: Consultant, Personal

Takeda: Research support, Institutional

American board of internal medicine: member of medical oncology exam committee, Personal

American Cancer Society: Section editor, Cancer journal, Personal

Research to practice: speaker at CME programs, Personal

Web MD: speaker at CME programs, Personal

Peerview: Speaker at CME programs, Personal

Onclive: Speaker at CME programs, Personal

Physicians Educational Resource: Speaker at CME program, Personal

Lilly Oncology: Consultant, Personal

COI Disclosure Certification

SSR

Confidentiality Agreement

SSR

Standards of Conduct Agreement

SSR

IASLC's Tax-Exempt Status

SSR

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

One issue that I would like to inform everyone is that I will assume the role of the Editor-in-Chief for the journal Cancer (American Cancer Society) on July 01, 2021 (this news release just came out today). I serve on the board of managers for PRECOG, LLC, which conducts clinical research in the United States. In addition, I serve on the board of Georgia CORE and Georgia Society of Clinical Oncology. I recently became the leader of the ASCO Cancer LinQ Leadership Council- this position actually wears the IASLC hat. I have been the chair of the ECOG- ACRIN

Thoracic Committee for the past 9 years. Best regards

Ram

Suresh S. Ramalingam, MD, FACP, FASCO

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?